Patents by Inventor Kuo-jang Kao

Kuo-jang Kao has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Therapeutic Biologic For Treatment Of Hepatocellular Carcinoma
    Publication number: 20220372109
    Abstract: The invention provides, inter alia, conjugates comprising a coagulating agent conjugated to an antibody, where the antibody specifically binds an extracellular domain epitope of a mammalian PLVAP protein. These agents specifically target HCC tumors and treat the HCC. The invention also provides methods of using these conjugates, such as methods of treating HCC by administering the conjugates provided by the invention or compositions provided by the invention, such as pharmaceutical compositions.
    Type: Application
    Filed: July 20, 2022
    Publication date: November 24, 2022
    Inventors: Kuo-Jang Kao, Yun-Hsin Wang
  • Therapeutic biologic for treatment of hepatocellular carcinoma
    Patent number: 11485771
    Abstract: Conjugates comprising a coagulating agent conjugated to an antibody, where the antibody specifically binds an extracellular domain epitope of a mammalian PLVAP protein, and methods of using such conjugates, including methods of treating HCC by administering the conjugates or compositions thereof, such as pharmaceutical compositions.
    Type: Grant
    Filed: July 16, 2019
    Date of Patent: November 1, 2022
    Assignee: Circular Commitment Company
    Inventors: Kuo-Jang Kao, Yun-Hsin Wang
  • Methods and agents for the diagnosis and treatment of hepatocellular carcinoma
    Patent number: 11339217
    Abstract: The present invention relates to methods of diagnosing and methods of treating hepatocellular carcinoma in a subject. The invention also relates to antagonists of PLVAP proteins, such as antibodies that specifically bind PLVAP proteins, as well as compositions and kits comprising antagonists of PLVAP proteins. The invention further relates to humanized antibodies that specifically bind PLVAP protein.
    Type: Grant
    Filed: June 24, 2019
    Date of Patent: May 24, 2022
    Assignee: Circular Commitment Company
    Inventors: Kuo-Jang Kao, Andrew T. Huang
  • Therapeutic biologic for treatment of hepatocellular carcinoma
    Patent number: 10906959
    Abstract: The invention provides conjugates comprising a coagulating agent conjugated to an antibody, where the antibody specifically binds an extracellular domain epitope of a mammalian PLVAP protein. These agents specifically target HCC tumors and treat the HCC. The invention also provides methods of using these conjugates, such as methods of treating HCC by administering the conjugates provided by the invention or compositions provided by the invention, such as pharmaceutical compositions.
    Type: Grant
    Filed: August 29, 2018
    Date of Patent: February 2, 2021
    Assignee: Circular Commitment Company
    Inventors: Kuo-Jang Kao, Yun-Hsin Wang
  • Therapeutic Biologic for Treatment of Hepatocellular Carcinoma
    Publication number: 20190338016
    Abstract: The invention provides, inter alia, conjugates comprising a coagulating agent conjugated to an antibody, where the antibody specifically binds an extracellular domain epitope of a mammalian PLVAP protein. These agents specifically target HCC tumors and treat the HCC. The invention also provides methods of using these conjugates, such as methods of treating HCC by administering the conjugates provided by the invention or compositions provided by the invention, such as pharmaceutical compositions.
    Type: Application
    Filed: July 16, 2019
    Publication date: November 7, 2019
    Inventors: Kuo-Jang Kao, Yun-Hsin Wang
  • Methods And Agents For The Diagnosis And Treatment Of Hepatocellular Carcinoma
    Publication number: 20190309062
    Abstract: The present invention relates to methods of diagnosing and methods of treating hepatocellular carcinoma in a subject. The invention also relates to antagonists of PLVAP proteins, such as antibodies that specifically bind PLVAP proteins, as well as compositions and kits comprising antagonists of PLVAP proteins. The invention further relates to humanized antibodies that specifically bind PLVAP protein.
    Type: Application
    Filed: June 24, 2019
    Publication date: October 10, 2019
    Inventors: Kuo-Jang Kao, Andrew T. Huang
  • Therapeutic biologic for treatment of hepatocellular carcinoma
    Patent number: 10400026
    Abstract: The invention provides conjugates comprising a coagulating agent conjugated to an antibody, where the antibody specifically binds an extracellular domain epitope of a mammalian PLVAP protein. These agents specifically target HCC tumors and treat the HCC. The invention also provides methods of using these conjugates, such as methods of treating HCC by administering the conjugates provided by the invention or compositions provided by the invention, such as pharmaceutical compositions.
    Type: Grant
    Filed: September 20, 2016
    Date of Patent: September 3, 2019
    Assignee: Circular Commitment Company
    Inventors: Kuo-Jang Kao, Yun-Hsin Wang
  • Methods and agents for the diagnosis and treatment of hepatocellular carcinoma
    Patent number: 10370445
    Abstract: The present invention relates to methods of diagnosing and methods of treating hepatocellular carcinoma in a subject. The invention also relates to antagonists of PLVAP proteins, such as antibodies that specifically bind PLVAP proteins, as well as compositions and kits comprising antagonists of PLVAP proteins. The invention further relates to humanized antibodies that specifically bind PLVAP protein.
    Type: Grant
    Filed: December 6, 2016
    Date of Patent: August 6, 2019
    Assignee: Circular Commitment Company
    Inventors: Kuo-Jang Kao, Andrew T. Huang
  • Therapeutic Biologic For Treatment Of Hepatocellular Carcinoma
    Publication number: 20180362614
    Abstract: The invention provides, inter alia, conjugates comprising a coagulating agent conjugated to an antibody, where the antibody specifically binds an extracellular domain epitope of a mammalian PLVAP protein. These agents specifically target HCC tumors and treat the HCC. The invention also provides methods of using these conjugates, such as methods of treating HCC by administering the conjugates provided by the invention or compositions provided by the invention, such as pharmaceutical compositions.
    Type: Application
    Filed: August 29, 2018
    Publication date: December 20, 2018
    Inventors: Kuo-Jang Kao, Yun-Hsin Wang
  • Methods and Agents for the Diagnosis and Treatment of Hepatocellular Carcinoma
    Publication number: 20170145092
    Abstract: The present invention relates to methods of diagnosing and methods of treating hepatocellular carcinoma in a subject. The invention also relates to antagonists of PLVAP proteins, such as antibodies that specifically bind PLVAP proteins, as well as compositions and kits comprising antagonists of PLVAP proteins. The invention further relates to humanized antibodies that specifically bind PLVAP protein.
    Type: Application
    Filed: December 6, 2016
    Publication date: May 25, 2017
    Inventors: Kuo-Jang Kao, Andrew T. Huang
  • Methods and agents for the diagnosis and treatment of hepatocellular carcinoma
    Patent number: 9545443
    Abstract: The present invention relates to methods of diagnosing and methods of treating hepatocellular carcinoma in a subject. The invention also relates to antagonists of PLVAP proteins, such as antibodies that specifically bind PLVAP proteins, as well as compositions and kits comprising antagonists of PLVAP proteins. The invention further relates to humanized antibodies that specifically bind PLVAP protein.
    Type: Grant
    Filed: July 18, 2014
    Date of Patent: January 17, 2017
    Assignee: China Synthetic Rubber Corporation
    Inventors: Kuo-Jang Kao, Andrew T. Huang
  • Therapeutic Biologic for Treatment of Hepatocellular Carcinoma
    Publication number: 20170000898
    Abstract: The invention provides, inter alia, conjugates comprising a coagulating agent conjugated to an antibody, where the antibody specifically binds an extracellular domain epitope of a mammalian PLVAP protein. These agents specifically target HCC tumors and treat the HCC. The invention also provides methods of using these conjugates, such as methods of treating HCC by administering the conjugates provided by the invention or compositions provided by the invention, such as pharmaceutical compositions.
    Type: Application
    Filed: September 20, 2016
    Publication date: January 5, 2017
    Inventors: Kuo-Jang Kao, Yun-Hsin Wang
  • Therapeutic biologic for treatment of hepatocellular carcinoma
    Patent number: 9493552
    Abstract: The invention provides, inter alia, conjugates comprising a coagulating agent conjugated to an antibody, where the antibody specifically binds an extracellular domain epitope of a mammalian PLVAP protein. These agents specifically target HCC tumors and treat the HCC. The invention also provides methods of using these conjugates, such as methods of treating HCC by administering the conjugates provided by the invention or compositions provided by the invention, such as pharmaceutical compositions.
    Type: Grant
    Filed: November 12, 2014
    Date of Patent: November 15, 2016
    Assignee: China Synthetic Rubber Corporation
    Inventors: Kuo-Jang Kao, Yun-Hsin Wang
  • Methods and agents for the diagnosis and treatment of hepatocellular carcinoma
    Patent number: 9394359
    Abstract: The present invention relates to methods of diagnosing, and methods of treating, hepatocellular carcinoma in a subject. The invention also relates to polypeptide antagonists of PLVAP proteins, including humanized and chimeric antibodies that specifically bind PLVAP proteins, as well as compositions and kits comprising such polypeptide antagonists.
    Type: Grant
    Filed: July 21, 2014
    Date of Patent: July 19, 2016
    Assignee: CHINA SYNTHETIC RUBBER CORPORATION
    Inventors: Kuo-Jang Kao, Andrew T. Huang
  • Therapeutic Biologic for Treatment of Hepatocellular Carcinoma
    Publication number: 20150140021
    Abstract: The invention provides, inter alia, conjugates comprising a coagulating agent conjugated to an antibody, where the antibody specifically binds an extracellular domain epitope of a mammalian PLVAP protein. These agents specifically target HCC tumors and treat the HCC. The invention also provides methods of using these conjugates, such as methods of treating HCC by administering the conjugates provided by the invention or compositions provided by the invention, such as pharmaceutical compositions.
    Type: Application
    Filed: November 12, 2014
    Publication date: May 21, 2015
    Inventors: Kuo-Jang Kao, Yun-Hsin Wang
  • Methods and Agents for the Diagnosis and Treatment of Hepatocellular Carcinoma
    Publication number: 20150017171
    Abstract: The present invention relates to methods of diagnosing, and methods of treating, hepatocellular carcinoma in a subject. The invention also relates to polypeptide antagonists of PLVAP proteins, including humanized and chimeric antibodies that specifically bind PLVAP proteins, as well as compositions and kits comprising such polypeptide antagonists.
    Type: Application
    Filed: July 21, 2014
    Publication date: January 15, 2015
    Inventors: Kuo-Jang Kao, Andrew T. Huang
  • Methods and Agents for the Diagnosis and Treatment of Hepatocellular Carcinoma
    Publication number: 20140322131
    Abstract: The present invention relates to methods of diagnosing and methods of treating hepatocellular carcinoma in a subject. The invention also relates to antagonists of PLVAP proteins, such as antibodies that specifically bind PLVAP proteins, as well as compositions and kits comprising antagonists of PLVAP proteins. The invention further relates to humanized antibodies that specifically bind PLVAP protein.
    Type: Application
    Filed: July 18, 2014
    Publication date: October 30, 2014
    Inventors: Kuo-Jang Kao, Andrew T. Huang
  • Methods and agents for the diagnosis and treatment of hepatocellular carcinoma
    Patent number: 8821880
    Abstract: The present invention relates to methods of diagnosing, and methods of treating, hepatocellular carcinoma in a subject. The invention also relates to polypeptide antagonists of PLVAP proteins, including humanized and chimeric antibodies that specifically bind PLVAP proteins, as well as compositions and kits comprising such polypeptide antagonists.
    Type: Grant
    Filed: September 9, 2009
    Date of Patent: September 2, 2014
    Assignee: China Synthetic Rubber Corporation
    Inventors: Kuo-Jang Kao, Andrew T. Huang
  • Methods and agents for the diagnosis and treatment of hepatocellular carcinoma
    Patent number: 8815240
    Abstract: The present invention relates to methods of diagnosing, and methods of treating, hepatocellular carcinoma in a subject. The invention also relates to antagonists of PLVAP proteins, such as antibodies that specifically bind PLVAP proteins, as well as compositions and kits comprising antagonists of PLVAP proteins. The invention further relates to humanized antibodies that specifically bind PLVAP protein.
    Type: Grant
    Filed: March 18, 2009
    Date of Patent: August 26, 2014
    Assignee: China Synthetic Rubber Corporation
    Inventors: Kuo-Jang Kao, Andrew T. Huang
  • Methods and Agents for the Diagnosis and Treatment of Hepatocellular Carcinoma
    Publication number: 20110262349
    Abstract: The present invention relates to methods of diagnosing, and methods of treating, hepatocellular carcinoma in a subject. The invention also relates to polypeptide antagonists of PLVAP proteins, including humanized and chimeric antibodies that specifically bind PLVAP proteins, as well as compositions and kits comprising such polypeptide antagonists.
    Type: Application
    Filed: September 9, 2009
    Publication date: October 27, 2011
    Inventors: Kuo-Jang Kao, Andrew T. Huang